From the labto the hospital

Experimental Therapy

Grup de terapèutica experimental a Vall d'Hebron

The group’s current aims are focused on identifying the subset of tumours that are most likely to respond to targeted breast cancer therapies with special focus on PI3K, CDK4/6 and PARP inhibitors. Studying the mode of action based on the hypothesis of drug combinations. Proposing new therapeutic strategies for treating breast cancer and developing preclinical models based on tumour explants in immunosuppressed mice.


We are working on developing PI3-K predictive pharmacodynamic biomarkers, as well as CDK4/6 inhibitors.  Revealing new mechanisms of resistance against BRCA1/2 germline therapy in breast cancer, and establishing a preclinical model of patients with breast cancer, to explore the hypotheses based on combination therapies.

Visit the research group’s page

Healthcare specialisations
Teaching units